, the net profit was Baht 43.31 million, decreased by 3.41 million or decreasing by 7.3 percents in which performance for the company and its subsidiaries in the current three-month period compared to the

total borrowings, decreasing from 69% of fiscal year 2017. To manage risk that might occur from the fluctuation in currency and interest rate of long-term a debenture in foreign currencies, the Company

THB 314.21 million, decreasing 53.38% from the end of last year. Total liabilities comprise mostly short-term loans from financial institutions, trade payables and other payables and long-term loans

Business in 9M/2018 was 1,106.80 million Baht, decreased by 66.57 million Baht or 5.67% as compared to same period of 2 017 due to the decreasing of household customers and the higher cost from purchasing

previous year. This came from decreasing in services revenue whereas sales revenues from medical devices still increased. Revenues from sales and services of EFORL and its subsidiaries in Q3/2018 increased

newl 0 per share t offering) with t 0.53 per sha 18 to 24 Dece are remaining onate to their g shareholde e newly issue ued ordinary issued ordina decreasing here is any s ng shareholdi (including the

quarter. The decreasing of selling expenses from property development business were as result of the absence revenue from the property development business while the company has recorded The Company

Unit: THB mm average cost of fund of the Company in 2019 decreased by 0.47% (decreasing from 3.88% in 2018 to 3.41% in 2019). During 2019, the Company had utilized additional short-term and long-term

do not exceed 1:1 and are in compliance with the 4 policy of the Company. The cost management of the Company is very efficient. The interest cost is lower than 3%, decreasing from 4% as a result of the

-bearing debt to equity ratio of 2.41x, decreasing from 2.49x as of 31 December 2019. This was caused by decreased interest-bearing liabilities due to repayment of long- term loans and leasing loans as well